1. Introduction {#sec1}
===============

Apicomplexan parasites are the cause of significant diseases of both humans and domesticated animals. Despite the current therapies available to treat these parasitic infections, the challenge of overcoming the rapid development of parasite drug resistance underscores the need for new treatments.

Recently we described the broad-spectrum anti-apicomplexan activity of tartrolon E (trtE), a secondary metabolite of symbiotic bacteria of shipworms ([@bib34]). Tartrolons are a class of macrolide dimers, or pseudodimers consisting of polyketide chains joined as diesters that commonly bind to boron. These compounds are produced by both marine and terrestrial bacteria and exhibit antibacterial ([@bib11]; [@bib20]; [@bib41]) and insecticidal activity ([@bib24]). We demonstrated that trtE inhibits many different apicomplexans at low nM concentrations in vitro, including *Cryptosporidium parvum, Toxoplasma gondii*, *Sarcocystis neurona*, *Plasmodium falciparum*, *Babesia spp.* and *Theileria equi.* In vivo efficacy of trtE has also been demonstrated, as the treatment of *C. parvum-*infected neonatal mice with trtE significantly reduced intestinal infection ([@bib34]).

No other compound with this broad activity against apicomplexans has been reported, which makes the identification of the mechanism of action of trtE particularly important. To gain insights into the compound\'s anti-parasitic mechanism, we conducted an RNA-Seq analysis of trtE treated *T. gondii*. This analysis identified a conserved gene of unknown function that was upregulated during trtE treatment. When this gene was disrupted, *T. gondii* parasites became significantly more resistant to trtE, supporting a role for this gene product in the parasite\'s response to trtE treatment. We name this gene *trg* for trtE responsive gene, and present bioinformatic analyses characterizing the gene and protein in *T. gondii* and related species.

2. Methods {#sec2}
==========

2.1. Parasites {#sec2.1}
--------------

*T. gondii* strains ME49 and RH were maintained by serial passage in human foreskin fibroblasts (HFF, ATCC SCRC-1041), cultured in DMEM supplemented with 15% fetal bovine serum as previously described ([@bib39]).

2.2. RNA-seq of trtE-treated *T. gondii* RH parasites {#sec2.2}
-----------------------------------------------------

Total RNA from *T. gondii* RH parasites treated with 24.2 nM trtE or 0.1% DMSO control was collected 4, 8, and 12 h post-treatment for RNA-Seq analysis. The details of the experimental analysis and results of the transcriptome are available in the GEO database (GSE140197). Briefly, the integrity and quantity of the total RNA samples were determined using a Fragment Analyzer™ (AATI, Ames, IA, USA). The RNA samples that satisfied the input requirement were used as input for the Illumina TruSeq Stranded Total RNA with Ribo-Zero® Gold sample preparation kit (Illumina, San Diego, CA, USA) following the manufacturer\'s instructions. The quality and molar concentration of the libraries were determined using the Fragment Analyzer. The libraries were pooled and sequenced using HiSeq 2500 High Output V4 chemistry (Illumina). The 75 million to 95 million reads per sample obtained were analyzed using the TopHat-Cufflinks pipeline. The expression level was estimated with Cuffdiff and represented as fragments per kilobase of exons per million mapped fragments (FPKM) to the *T. gondii* GT1 genome available on ToxoDB ([@bib14]) (<http://toxodb.org>). Genes were considered deferentially expressed when both the p-value and q-value, estimated based using a negative binomial model, were below a significance value of 0.05. The RNA-Seq experiment was conducted once.

2.3. Reverse transcriptase quantitative PCR {#sec2.3}
-------------------------------------------

To confirm RNA-Seq results, HFF cells were infected with 2 × 10^6^ *T. gondii* RH strain parasites per well in six-well plates. After an additional 24 h of incubation, infected cells were treated with 24.2 nM trtE, 10 μM pyrimethamine, or 0.1% DMSO carrier control in triplicate. RNA was extracted from treated, infected cells using an RNeasy® Kit (Qiagen, Germantown, MD, USA) at 1, 2, and 4 h post treatment. Synthesis of cDNA for each RNA sample was accomplished using iScript™ cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA) using 1 μg of RNA template. Quantitative PCR was performed on the CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad) using SsoAdvanced™ Universal SYBR® Green Supermix (Bio-Rad). The amplification conditions were: 98 °C for 30 s, 40 cycles of denaturation at 98 °C for 30 s, and annealing/extension at 60 °C for 30 s. A melting curve, representing a 1 s hold at every 0.5 °C between 65° and 95 °C, was generated to confirm a single peak for each primer pair. Primer sequences and product sizes for each pair are provided in [Table S1](#appsec1){ref-type="sec"}. Relative expression of *TGGT1_272370* (hereafter referred to as *trg*, GenBank accession no: **[XM_018781656]{.ul}**) and bradyzoite antigen 1 (*bag1*; GenBank accession no: **[XM_002365075]{.ul}**) was determined using the 2^−ΔΔCt^ method ([@bib25]) using expression of the endogenous parasite actin gene (*act 1*; GenBank accession no: **[XM_002369622]{.ul}**) for normalization.

To investigate the dose-dependent expression of *trg* during trtE treatment, HFF cells were infected with 2 × 10^6^ *T. gondii* RH parasites in six-well plates. Twenty-four hours post-infection, infected cells were treated with 60.5, 24.2, 12.1, 6.1, 1.2 nM trtE or 0.1% DMSO control for 4 h before RNA extraction. Three technical replicates were performed on each sample. Data analysis was accomplished using GraphPad Prism 8.00 Software (GraphPad Software, San Diego, CA, USA).

2.4. Bioinformatics analysis of *trg* predicted protein product {#sec2.4}
---------------------------------------------------------------

The complete amino acid sequence of the ME49 strain Trg protein (GenBank accession no: **[XP_018636692]{.ul}**) was retrieved from the National Center for Biotechnology Information (NCBI) database. The presence of multiple post-translational modification sites were predicted including phosphorylation sites using NetPhos 3.1 server ([@bib4]) (<https://services.healthtech.dtu.dk/service.php?NetPhos-3.1>) with kinase-specific predictions ([@bib5]), and palmitoylation sites using CSS-Palm 4.0 ([@bib38]) (<http://csspalm.biocuckoo.org/online.php>). The TMHMM server v.2.0 ([@bib22]) (<https://services.healthtech.dtu.dk/service.php?TMHMM-2.0>) was used to estimate transmembrane domains. Both WoLF PSORT ([@bib18]) (<https://wolfpsort.hgc.jp>; using "Animal" as the organism type) and data from hyperplexed Localization of Organelle Proteins by Isotopic Tagging (hyperLOPIT) experiments using extracellular *T. gondii* tachyzoites (<https://proteome.shinyapps.io/toxolopittzex/>) accessed through ToxoDB ([@bib14]) (<http://toxodb.org>) were used to predict Trg localization. Identification of short linear motifs in the Trg sequence was accomplished using the eukaryotic linear motif (ELM) resource ([@bib16]) (<http://elm.eu.org>) filtering for predicted cell compartment and *T. gondii* taxonomic context. Protein sequences of *Trg* homologs in other coccidia were identified by searching NCBI Database resources ([@bib33]) using the basic local alignment search tool ([@bib1]), ToxoDB ([@bib14]) (<http://toxodb.org>), and Ensembl Genomes ([@bib19]) (<http://www.ensemblgenomes.org>), aligned using the Clustal W ([@bib48]) algorithm of the AlignX module of Vector NTI (Life Technologies, Rockville, MD, USA) and evaluated for identity and similarity to Trg using the Sequence Manipulation Suite ([@bib45]) (<http://www.bioinformatics.org/sms2/ident_sim.html>). Domain families for protein sequences of Trg and homologs were identified using the NCBI conserved domain database ([@bib26]) (<https://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml>).

2.5. CRISPR/Cas9-mediated deletion of *trg* {#sec2.5}
-------------------------------------------

A clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 method (CRISPR/Cas9) was designed to knock out *trg* in the *T. gondii* ME49 ΔHPT:LUC strain ([@bib49]). A guide sequence (5′-AGTGGATGCGGAGCCTGCTG-3′) targeting *trg* was identified using the Eukaryotic Pathogen CRISPR guide RNA/DNA Design Tool ([@bib47]) (<http://grna.ctegd.uga.edu>) based on the efficiency score against the *T. gondii* ME49 genome available on ToxoDB ([@bib14]) (<http://toxodb.org>). The pSAG1:CAS9-U6:sg272370 ([Fig. 1](#fig1){ref-type="fig"}A) was prepared by replacing the single guide (sgRNA) sequence of the pSAG1:CAS9-U6 plasmid ([@bib42]) with the identified guide sequence targeting *trg* using primers listed in [Table S1](#appsec1){ref-type="sec"} and the Q5® Site-Directed Mutagenesis Kit (New England Biolabs, Ipswich, MA, USA). A second plasmid provided the regions of sequence identity for homologous recombination and the *mCherry* gene substitution for *trg*. This plasmid, pBC-GFP-272370-mCherry ([Fig. 1](#fig1){ref-type="fig"}B, designated the "flanking plasmid"), was generated by Gibson assembly® (New England Biolabs) of PCR amplicons of 1 kb upstream and 1 kb downstream flanking sequences of *trg*, the *mCherry* expression cassette (pSAG1-mCherry-5′ DHFR 3′ UTR) amplified from the pBC-GFP-mCherry plasmid and the linearized pBC-GFP-mCherry plasmid (containing a GFP expression cassette, pTUB1-eGFP-SAG1 3′ UTR). Plasmids were produced in transfected *E. coli* D5α (New England Biolabs) and isolated using the QIAGEN Plasmid Maxi Kit (QIAGEN).*T. gondii* ME49 ΔHPT:LUC tachyzoites were transfected with the pSAG1:CAS9-U6:sg272370 and flanking plasmids by electroporation ([@bib44]).Fig. 1CRISPR/Cas9 mediated deletion of *trg.* (A) The plasmid used to provide *T. gondii-*optimized expression of the Cas9 enzyme and sgRNA for targeting *trg*. (B) The plasmid containing a *mCherry* expression cassette (red, pSAG1-mCherry-DHFR 3′ UTR) surrounded by 1 kb areas of sequence identity to the flanking regions of *trg* (grey) and a *GFP* expression cassette (green, pTUB1-eGFP-SAG1 3′ UTR) used to provide a repair template for homologous recombination of disrupted *trg* locus. (C) Expression of *Cas9* with sg272370 guide RNA (pink) targeted *trg* and induced a double-stranded break. Linearized pBC-mCherry-272370-GFP plasmid provided a template for double homologous recombination, which is designed to replace the entire *trg* gene with *mCherry* and lose *GFP* for sorting. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)Fig. 1

The desired mutant that successfully replaced *trg* with *mCherry* by homologous recombination must be mCherry^+^, and GFP^−^ ([Fig. 1](#fig1){ref-type="fig"}C). Therefore, parasites that are were mCherry^+^ and GFP^−^ were selected by cell sorting using BD FACSAria™ II (BD Biosciences, San Jose, CA, USA). The selected population was cloned by limiting dilution, as previously described ([@bib36]). Eight individual clones were isolated.

2.6. Isolation of genomic DNA from *T. gondii* parasites {#sec2.6}
--------------------------------------------------------

Total genomic DNA (gDNA) from parental and knockout parasites was isolated following methods described previously ([@bib29]). Briefly, parasites were harvested from infected flasks by syringe-lysis using a 25G needle and pelleted by centrifugation at 500×*g* for 10 min. The pellets were resuspended in 400 μl of TELT lysis buffer (2.5 M LiCl, 50 mM Tris-HCl pH 8.0, 4% (v/v) Triton X-100, 62.5 mM EDTA) supplemented with 10 μl of 10 mg/ml RNase A (Thermo Fisher Scientific, Waltham, MA, USA), mixed by gentle rotation until completely lysed, and combined with an equal volume of phenol/chloroform. The solutions were mixed as before and centrifuged for 5 min at 15,000×*g* to separate the nucleic acids in the aqueous phase from proteins and lipids in the interface and organic phase. For optimal recovery, we repeated the extraction on the spent phenol/chloroform using an equal volume of TELT lysis buffer. The nucleic acids from the pooled aqueous phases were isolated by ethanol precipitation ([@bib40]) and dissolved in 10 mM Tris-HCl pH 8.0, 0.5 mM EDTA.

2.7. PCR test for *trg* {#sec2.7}
-----------------------

A total of 25 ng of gDNA from *T. gondii* ME49 ΔHPT:LUC parental strain and each of the eight ME49 ΔHPT:LUC Δ*trg* clones, was mixed with primers designed to amplify a 172 bp fragment of *trg* ([Table S1](#appsec1){ref-type="sec"}) and Q5® Hot Start High-Fidelity 2X PCR Master Mix (New England Biolabs). The amplification conditions were: 98 °C for 30 s, 35 cycles of denaturation at 98 °C for 5 s, annealing at 68 °C, extension at 72 °C for 20 s, and a final extension at 72 °C for 2 min. Reactions were resolved on a 2% agarose gel using a 100 bp DNA ladder (New England Biolabs) for size estimation.

2.8. Southern blot analysis {#sec2.8}
---------------------------

Approximately 5 μg of gDNA from each strain was digested overnight with the restriction endonuclease Bsu36I (New England Biolabs) and resolved on a 0.8% agarose gel using a DIG-labeled DNA Molecular Weight Marker II (MilliporeSigma, St. Louis, MO, USA) for size estimation. After blotting and u. v. crosslinking to a nylon membrane (BrightStar™- Plus Positively Charged Nylon Membrane, Thermo Fisher Scientific), the membrane was hybridized to digoxigenin (DIG)-labeled *mCherry* gene probes generated by PCR using the PCR DIG Probe Synthesis Kit (MilliporeSigma), the primers shown in [Table S1](#appsec1){ref-type="sec"}, and pBG-GFP-mCherry plasmid template. Hybridizations were performed overnight at 47 °C using DIG Easy Hyb™ hybridization buffer (MilliporeSigma), and final washes were made in 0.1X saline sodium citrate (SSC)/0.1% sodium dodecyl sulfate (SDS) solution for 15 min at 68 °C. Chemiluminescence of probe-target hybrids was detected by anti-DIG-alkaline phosphatase antibody (MilliporeSigma) and visualized using the ChemiDoc Touch™ Imaging System (Bio-Rad).

2.9. In vitro inhibitor response assays {#sec2.9}
---------------------------------------

HFF cells in 96-well plates were infected with 5 × 10^4^ parental or *trg* knockout clones for 24 h before treatment with eight 2-fold dilutions of trtE (60.5--0.5 nM) or DMSO control with three technical replicates for each concentration. Treated parasites were incubated at 37 °C and 5% CO~2~ for 24 h before measuring luciferase (LUC) activity using the Bright-Glo™ Luciferase Assay System (Promega, Madison, WI, USA). Inhibition was calculated by comparing the LUC activity of trtE-treated and untreated parasites. Estimation of the EC~50~ value for trtE treatment using data from three independent experiments was accomplished using a four-parameter logistic regression, and comparisons between estimated EC~50~ values of the strains were made using an extra sum-of-squares F test using GraphPad Prism 8.00 Software (GraphPad Software).

3. Results {#sec3}
==========

3.1. *T. gondii* responds to trtE treatment by upregulating expression of *trg* {#sec3.1}
-------------------------------------------------------------------------------

To identify proteins that may be targeted by trtE, we conducted a preliminary RNA-Seq experiment to examine the transcriptome of trtE treated *T. gondii* parasites. Of the 90 significantly and differentially expressed *T. gondii* genes over the 12-hr. treatment period ([Fig. S1](#appsec1){ref-type="sec"}, [Table S2](#appsec1){ref-type="sec"}), only *trg* ([Fig. 2](#fig2){ref-type="fig"}A) and *TGGT1_311100* ([Fig. S1](#appsec1){ref-type="sec"}) were upregulated within 4 h of treatment and remained upregulated throughout the entire treatment period.Fig. 2*T. gondii* responds to trtE treatment by upregulating *trg* in a rapid dose-dependent manner. (A) Changes in transcript abundance of *trg* in *T. gondii* parasites treated with 24.2 nM trtE or DMSO carrier control. (B) Expression of *trg* quantified by RT-qPCR of RNA extracted from *T. gondii* parasites treated with trtE (24.2 nM), known inhibitory compound pyrimethamine (Pyr, 10 μM), or 0.1% DMSO carrier control at 1, 2, 4 h post treatment. Three technical replicates were performed. Treatment of parasites with trtE significantly increased the expression of *trg* at 4 h post treatment (*p* ≤ 0.0001). (C) Expression of *trg* quantified by RT-qPCR of RNA extracted from *T. gondii* parasites treated with various concentrations of trtE or 0.1% DMSO carrier control. RNA was isolated from each condition 4 h post treatment and RT-qPCR samples were run in triplicate. Fold-change in gene expression for RT-qPCR experiments was calculated using the 2^−ΔΔCt^ method and normalized by the expression of parasite actin. The relationship between expression of *trg* and concentration of the trtE treatment was determined to be linear (R^2^ = 0.7776, *p* ≤ 0.0001).Fig. 2

To confirm RNA-Seq results, we treated *T. gondii* ME49 strain with trtE or DMSO for 1--4 h and measured the expression of *trg* and *TGGT1_311100* homologs by RT-qPCR. Expression of *trg* but not *TgME49_311100* ([Fig. S2](#appsec1){ref-type="sec"}), was upregulated within 4 h of trtE-treatment ([Fig. 2](#fig2){ref-type="fig"}B). Treatment with the known *T. gondii* inhibitor pyrimethamine did not affect *trg* transcript abundance. The expression of *bag1* was decreased after 4 h of trtE treatment ([Fig. S2](#appsec1){ref-type="sec"}). Additionally, we observed a linear dose-dependent expression of *trg* 4 h after the treatment of *T. gondii* parasites with trtE ([Fig. 2](#fig2){ref-type="fig"}C).

3.2. Bioinformatic analyses of *trg* predicted protein sequence {#sec3.2}
---------------------------------------------------------------

The ME49 strain *trg* gene is 12,805 bp in length comprised of 9 exons, of which 7107 bp encode a protein of 2368 aa. To gain insight into the function of the protein, the presence of predicted post-translational modifications and functional motifs was investigated. NetPhos 3.1 ([@bib4]) was used to predict 137 potential sites with a probability score higher than 75%. Of these, three positions (T393, S502, S530) were identified as protein kinase A (PKA) family-specific sites and six positions (S134, S174, T443, S1076, T2172, T2300) were identified as protein kinase C (PKC) family-specific sites; the rest were unspecified. The predicted phosphorylation sites were distributed as 75.2% (103/137) serine, 22.6% (31/137) threonine, and 2.2% (3/137) tyrosine. Predicted palmitoylation sites identified by CSS-Palm 4.0 ([@bib38]) clustered around two areas (C635, C636, C641, C646; C1637, C1647, C1684) of Trg. While bioinformatic analyses predicted multiple phosphorylation and palmitoylation sites, only one residue (T2262) has experimental evidence of phosphorylation ([@bib50]). Trg was not identified in the palmitoylated proteins discovered by DIA-MS ([@bib12]) or ABE-MS ([@bib7]). To examine the predicted localization of Trg, we used both computational prediction tools and reports of experimental proteome data of tagged proteins. TMHMM v2.0 ([@bib22]) predicted five transmembrane domains in the protein sequence (positions 610--632, 748--770, 1618--1640, 1653--1675, and 2192--2214). WoLF PSORT ([@bib18]) analysis of the protein sequence predicted the uncharacterized protein to be localized to the plasma membrane with 81.25% (26/32) nearest neighbors associated with the plasma membrane, 12.5% (4/32) neighbors associated with the nucleus, and 6.25% (2/32) neighbors associated with the cytoplasm. The hyperLOPIT proteomic data for *T. gondii* tachyzoites accessed through ToxoDB ([@bib14]) also localized Trg to the plasma membrane.

To look for known functional domains in Trg, we examined the protein sequence for linear motifs. Filtering the results of the Eukaryotic Linear Motifs (ELM) search ([@bib16]) for motifs common to *T. gondii* and plasma membrane proteins identified four (1809--1812, 1814--1817, 1862--1865, 1919--1922, 2129--2132) tyrosine-based endocytic sorting signals (ELM accession no: ELME000120) in *Trg*. These Yxxphi motifs are found in the cytosolic tail of membrane proteins and act as a sorting signal that directs traffic within the endosomal and the secretory pathways.

Because trtE is broadly effective against multiple apicomplexan parasites, we looked for proteins that shared sequence identity with Trg among the apicomplexa. However, after searching various databases (NCBI, [ToxoDB.org](http://ToxoDB.org){#intref0080}, and Ensembl Genomes), we identified homologs with similar predicted transmembrane structures in the coccidia only ([Table 1](#tbl1){ref-type="table"}, [Fig. 3](#fig3){ref-type="fig"}, and [Fig. S3](#appsec1){ref-type="sec"}). No homologs of Trg were found in other more distantly related apicomplexans.Table 1Identity and similarity of Trg homologs to TgTrgTable 1OrganismGeneIDAccession No.Identity (%) \[No. aa\]Similarity (%) \[No. aa\]Coverage (%)*H. hammondi H.H.34*HHA_272370KEP66945.173.31 \[1736\]77.53 \[100\]84*B. besnoiti Ger 1*BESB_032870XP_029215099.135.43 \[958\]47.08 \[315\]30*N. caninum Liverpool*NCLIV_034940CEL67703.132.07 \[813\]42.96 \[276\]48*C. suis Wien I*CSUI_002351PHJ23796.120.33 \[615\]31.93 \[351\]23*C. cayetanensis NF1_C8*LOC34621828XP_02618964717.09 \[443\]25.27 \[212\]11*E. tenella Houghton*ETH_00032795CDJ37990.116.08 \[411\]23.79 \[197\]12*S. neurona SN3*SN3_00202415NA[a](#tbltbl1fna){ref-type="table-fn"}10.19 \[269\]18.55 \[221\]14[^3]Fig. 3Schematic of identified homologs of Trg in coccidian parasites. Protein homologs to Trg (TGME49_272370) with predicted transmembrane domains (green) in order of descending sequence similarity. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)Fig. 3

3.3. Deletion of *trg* results in an increase in parasite resistance to trtE-treatment {#sec3.3}
--------------------------------------------------------------------------------------

To determine if Trg played a direct role in the response of *T. gondii* parasites to treatment with trtE, we generated *trg* deletion mutants using CRISPR/CAS9. After the selection of putative knockout parasites by FACS, and two rounds of cloning by limiting dilution, the presence of *trg* was assessed by PCR in eight ME49 ΔHPT:LUC Δ*trg* isolates ([Fig. 4](#fig4){ref-type="fig"}A); and screened for erroneous insertion events by Southern blot analysis ([Fig. 4](#fig4){ref-type="fig"}B). We were unable to detect *trg* in ME49ΔHPT:LUC Δ*trg* clones by PCR ([Fig. 4](#fig4){ref-type="fig"}A), indicating disruption of the gene. No erroneous insertion events of the *mCherry* expression cassette into the chromosome of ME49ΔHPT:LUC Δ*trg* clones were detected by Southern blot ([Fig. 4](#fig4){ref-type="fig"}B). There were no apparent differences in growth rates between wt and the ME49 ΔHPT:LUC Δ*trg* mutants, as was previously observed ([@bib43]).Fig. 4Deletion of *trg* increases parasite resistance to trtE treatment. (A) PCR detecting *trg* in gDNA isolated from *T. gondii* ME49ΔHPT:LUC parental line (P) and ME49 ΔHPT:LUC Δ*trg* clones. The anticipated 172 bp amplicon is detected in the parental line (white triangle) but was absent in the Δ*trg* clones. (B) Southern blot analysis of gDNA from the parental line and Δ*trg* clones digested with Bsu36I using *mCherry* probe to detect insertion events. The single anticipated 7.6 kb fragment present in all Δ*trg* clones (black triangle) was absent from the parental sample. (C) Parental (ME49 ΔHPT:LUC) and three Δ*trg* gene deletion mutants infected host cells for 24 h before being treated with varying concentrations of trtE. The growth of each strain was evaluated 24 h post treatment by LUC expression. Samples were run in triplicate, and three independent experiments performed. Estimation of the EC~50~ for each strain was accomplished using a four-parametric logistic regression in GraphPad Prism. The curve generated for the parental strain (R^2^ = 0.9797) estimated the EC~50~ to be 3.027 ng/ml (2.309--3.968; 95% CI). One curve adequately fit all the data from the three Δ*trg* clones tested (R^2^ = 0.9215, *p* = 0.16) with an estimated average EC~50~ of 5.088 ng/ml (4.144--6.247; 95% CI), which was significantly different from the EC~50~ of the parental line by extra sum-of-squares F test (*p* = 0.0004).Fig. 4

We compared the susceptibility of the parental strain and three of the eight ME49 ΔHPT:LUC Δ*trg* clones (1, 3, and 4) to trtE-treatment by quantifying the EC~50~ of the compound for each clone. ME49 ΔHPT:LUC Δ*trg* parasites were, on average 68% more resistant to trtE treatment than the ME49 ΔHPT:LUC parental line ([Fig. 4](#fig4){ref-type="fig"}C) with an estimated EC~50~ of 5.088 ng/ml (4.144--6.247 ng/ml; 95% CI) for the 3 deletion mutants clones as compared to an EC~50~ of 3.027 ng/ml (2.309--3.968 ng/ml; 95% CI) for the parental line.

4. Discussion {#sec4}
=============

This study has identified a component of the response of *T. gondii* parasites to the pan-anti-apicomplexan compound, trtE. Because trtE-treated *T. gondii* parasites die within 1 h of treatment ([@bib34]), genes that were differentially expressed after 4 h of treatment were targeted in this study. RNA-Seq of trtE-treated *T. gondii* parasites identified five genes in addition to *trg* (*TGGT1_311100, TGGT1_233460*, *TGGT1_214080, TGGT1_311425*, and *TGGT1_310740*) that were differentially expressed after 4 h of treatment ([Fig. S1](#appsec1){ref-type="sec"} and [Table S2](#appsec1){ref-type="sec"}). Two of these genes have characterized protein products (GeneID:protein; *TgME49_214080*:toxofilin, and *TgME49_233460*:SRS29B:SAG1). Toxofilin is an actin-binding protein ([@bib37]) that has been demonstrated to dissemble host actin and facilitate rapid parasite invasion of host cells ([@bib9]). The parasite surface protein SAG1 has been shown to play an active role in attachment and invasion of *T. gondii* tachyzoites ([@bib30]) and anti-SAG1 antibodies partially block invasion ([@bib31]). The expression of both genes was downregulated 4 h post trtE-treatment suggesting trtE may affect tachyzoite invasion into host cells. Pretreatment of tachyzoites with trtE prevents the parasite from establishing infection, but it was not determined if growth inhibition was pre or post-invasion ([@bib34]). Of the remaining genes differentially expressed within 4 h of treatment, only *trg* and *TGGT1_311100* were significantly upregulated throughout the entire RNA-Seq experiment; these genes were selected for further study.

Using qRT-PCR, we confirmed that the *trg* transcript (but not *TGGT1_311100*) was significantly upregulated in a rapid, dose-dependent manner in response to trtE treatment. This observation appears to be specific to trtE-treatment and not related to a general inhibition of the parasites since treatment with the anti-*Toxoplasma* compound pyrimethamine did not induce an increase in *trg* transcripts. Stress can cause *T. gondii* parasites to form bradyzoites in vitro ([@bib27]). However, trtE treatment reduced expression of the bradyzoite-specific gene *bag1* after 4 h of treatment, suggesting that the increase in expression of *trg* is not related to stress-associated bradyzoite formation. This observation is corroborated by studies showing that *trg* expression is not upregulated during bradyzoite formation ([@bib2]). In general, it appears that *trg* is not stage-specific as transcripts are detected during the merozoite ([@bib3]), oocyst, tachyzoite, and bradyzoite stages ([@bib13]). In a CRISPR genome-wide loss of function screen ([@bib43]), *trg* was found to be dispensable and, consistent with this report, we did not observe any obvious differences in growth rate between the parental and the *trg* knock out clones.

Bioinformatic analysis of the Trg sequence did not provide definitive clues as to the function of the protein. Trg has multiple transmembrane domains; it likely localizes to the plasma membrane and is a substrate for phosphorylation. The predictions for localization and endosomal targeting, common to membrane-bound proteins, are supported by both mass spectrometry data that identified the protein in the membrane fraction of *T. gondii* RH parasites ([@bib10]), and hyperLOPIT proteome data of extracellular tachyzoites (<https://proteome.shinyapps.io/toxolopittzex/>). There is experimental evidence that one of the predicted threonine phosphorylation sites (T2262) of Trg is phosphorylated ([@bib50]). Altogether these observations suggest the protein may play a role in a signaling cascade.

The *trg* gene is conserved amongst coccidia, and homologs were identified in *Besnoitia besnoiti*, *Cyclospora cayetanensis*, *Cytoisopora suis, Eimeria tenella*, *Hammondia hammondi, N. caninum,* and *S. neurona* ([Table 1](#tbl1){ref-type="table"}, [Fig S3](#appsec1){ref-type="sec"}). Of the coccidia, we have confirmed the activity of trtE against *S. neurona* ([@bib34]). Homologs to Trg in other trtE-sensitive apicomplexans may have sufficiently diverged such that we could not identify them by protein sequence identity, especially as there are no identified functional motifs in Trg*.* Alternatively, this response to trtE may be unique to the coccidians, and other mechanisms may be operating in *Plasmodium*, the piroplasms, and *Cryptosporidium.*

We anticipate that trtE has potassium ionophore activity since it is structurally similar to the known potassium ionophores trtB ([@bib46]) and boromycin ([@bib32]; [@bib35]). Ionophores are a promising source of treatments for drug-resistant parasites ([@bib21]). For example, monensin, a sodium ionophore isolated from the bacterium *Streptomyces cinnamonensis,* has activity against *Plasmodium spp., C. parvum,* and *T. gondii* ([@bib8]; [@bib17]; [@bib28]). Using a forward genetic screen to identify mutant *T. gondii* parasites resistant monensin, Garrison and Arrizabalaga found that the disruption of a mitochondrial DNA repair enzyme (*TgMSH-1*) contributed to parasite resistance to both monensin and the potassium ionophore salinomycin ([@bib15]). A study of the transcriptomic response of *T. gondii* parasites to monensin and salinomycin identified significant upregulation of histones and other genes associated with cell cycle arrest ([@bib23]). However, the transcriptomic profile of trtE-treated *T. gondii* (. [Table S2](#appsec1){ref-type="sec"} and. [Fig S1](#appsec1){ref-type="sec"}) was not in any way similar to that of monensin/salinomycin-treated parasites, suggesting that trtE has a different mechanism of action from these ionophores.

Using a combination of transcriptomic and genomic strategies, we identified a conserved coccidian gene that plays a role in the susceptibility of *T. gondii* parasites to the anti-apicomplexan compound, trtE. The function of the *trg* gene product remains entirely unclear, as does its relevance to the mechanism of action of trtE against non-coccidian apicomplexans. Further study into the function of Trg may clarify the specific mechanism of action of trtE against coccidans and identify a new drug target common to coccidian parasites of human and animal importance.
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Appendix A. Supplementary data {#appsec1}
==============================

The following are the supplementary data related to this article:Multimedia component 1Alignment of Trg homologs. Protein sequences for all homologs of Trg identified in this study were aligned using Clustal W and annotated using the AlignX module of Vector NTI.Multimedia component 1Multimedia component 2Multimedia component 2Multimedia component 3Multimedia component 3figs1RNA-Seq results. Differentially expressed genes of trtE-treated *T. gondii* RH parasites at 4, 8, and 12 h post treatment as determined by RNA-seq.figs2RT-qPCR verification of RNA-Seq results. Expression of *trg*, *TGGT1_311100*, and *bag1* transcripts in RNA extracted from *T. gondii* parasites treated with trtE (24.2 nM, red) or DMSO carrier control (0.1%, black) at 1, 2, and 4 h post treatment. Fold-change in gene expression was calculated using the 2^−ΔΔCt^ method with three replicates. Treatment of parasites with trtE significantly increased the expression of *trg* at all time points (*p* = 0.04, 0.01, and 0.004 at 1, 2, 4 h, respectively). Expression of *TGGT1_311100* during trtE treatment was not significantly different from treatment with DMSO (*p* = 0.4, 0.5, and 0.7 at 1, 2, 4 h respectively). At 4 h post treatment with trtE, expression of bradyzoite-specific gene *bag1* was significantly lower (*p* = 0.001) than DMSO-treated parasites. Three technical replicates were performed on all samples.
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